Sensory Organ Drugs - United Arab Emirates

The Sensory Organ Drugs market in the United Arab Emirates is predicted to experience significant growth in the coming years.
By 2024, the projected revenue is expected to reach US$44.57m.
This growth is anticipated to continue, with an estimated annual growth rate of -2.38% from 2024 to 2029.
As a result, the market volume is projected to reach US$39.51m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in the Sensory Organ Drugs market.
In 2024, United States is projected to generate US$13.98bn in revenue.
The United Arab Emirates is experiencing a growing demand for sensory organ drugs due to an increase in age-related eye and ear disorders.

Definition:
This market covers ophthalmologicals and otologicals, i.e., drugs for the sensory organs eye and ear, respectively. Ophthalmologicals are used to treat diseases of the eye such as wet age-related macular degeneration, geographic atrophy, and glaucoma. Typical dosage forms are eye drops or injections into the eye (intravitreal) and, in the case of otologicals, through the eardrum into the middle ear.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Regeneron Pharmaceuticals, Novartis, Bayer, Alcon, AbbVie

Ophthalmologicals
Otologicals

Respiratory system
Ophthalmic devices, such as diagnostic and surgical devices or glasses and contact lenses
Dermatology, skin treatment
Painkillers, analgesics

The Sensory Organ Drugs market in United Arab Emirates has been experiencing steady growth in recent years.

Customer preferences: Customers in the United Arab Emirates have been increasingly interested in sensory organ drugs due to the high prevalence of eye and ear disorders in the region. The aging population in the country has also contributed to the increasing demand for these drugs.

Trends in the market: The market for sensory organ drugs in the United Arab Emirates has been growing steadily due to the increasing prevalence of eye and ear disorders in the country. The market has also been driven by the increasing adoption of advanced technologies in the development of drugs for sensory organ disorders. Additionally, the increasing awareness about the importance of early diagnosis and treatment of sensory organ disorders has contributed to the growth of the market.

Local special circumstances: The United Arab Emirates has a high prevalence of eye and ear disorders due to factors such as the dry climate, exposure to dust, and genetic predisposition. This has led to a high demand for sensory organ drugs in the country. Additionally, the country has a large aging population, which has contributed to the increasing demand for these drugs.

Underlying macroeconomic factors: The United Arab Emirates has a strong economy, which has contributed to the growth of the sensory organ drugs market in the country. Additionally, the government has been investing heavily in the healthcare sector, which has led to the development of advanced technologies for the treatment of sensory organ disorders. The country's strategic location has also made it an attractive market for pharmaceutical companies looking to expand their presence in the Middle East.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.